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ABSTRACT - PURPOSE: Triple therapy for HCV-1 infection consists in boceprevir or telaprevir, ribavirin 
and PEG-interferon. Telaprevir is a P-glycoprotein substrate and it is metabolized by CYP3A4/5. No data 
have been published on intracellular penetration of telaprevir. We determined peripheral blood mononuclear 
cells (PBMCs) and trough plasma S and R telaprevir isomers concentrations; moreover, we evaluated the 
influence of some single nucleotide polymorphisms (SNPs) on these pharmacokinetic data after 1 month of 
triple therapy in humans. METHODS: Plasma and intracellular telaprevir concentrations were determined at 
the end of dosing interval (Ctrough) using ULPC-MS/MS validated methods; allelic discrimination was 
performed through real-time PCR. RESULTS: Median telaprevir Ctrough plasma concentrations were 2579 
ng/mL and 2233 ng/mL for the pharmacologically more active S, and R, enantiomers, respectively, with 
median S/R plasma ratio of 1.11. In PBMC, the medians were 6863 ng/mL and 1096 ng/mL for S and R, 
respectively, with median S/R being 5.73. The PBMC:plasma ratio for S was 2.59 for R. Plasma ribavirin 
concentrations were directly correlated with plasma S-telaprevir concentrations. In linear regression analysis, 
only CYP24A1_rs2585428 SNP (p=0.003) and body mass index (p=0.038) were able to predict S-telaprevir 
PBMC concentrations. CONCLUSIONS: Our preliminary data could increase the understanding of 
mechanisms underlying telaprevir intracellular and plasma exposure, suggesting the implementation of 
pharmacogenetics in these drug kinetic studies. 
 
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For 
Readers”) may comment by clicking on ABSTRACT on the issue’s contents page. 
____________________________________________________________________ 
 
INTRODUCTION 
 
For many years, “dual therapy” with pegylated 
(PEG) interferon α (IFNα) and ribavirin (RBV) 
was considered the standard treatment. The role of 
this drug consists in a host immunomodulation and 
in an indirect antiviral effect, since they do not 
target HCV genome or proteins(1). In 2011the first 
direct-acting antivirals, boceprevir (BOC) and 
telaprevir (TLV) were approved by the United 
States Food and Drug Administration for use as 
“triple therapy” in combination with PEG-
IFNα/RBV in patient affected by HCV-1(2). Both 
these direct-acting antivirals act on HCV NS3/4A 
protease and show two different isomeric forms (3, 
4).  
The main limitation of these treatments was 
the increase of some already known adverse events 
of double therapy, such as hemolytic anemia (5-
7).This increased toxicity seems to be due to 
increased renal impairment risk by TLV, leading to 
reduced RBV elimination, thus elevated  
intracellular concentration, thereby,  hemolysis(8, 
9). 
RBV, and other anti-HCV drugs, target on 
hepatocytes, but monitoring liver drug 
concentration is difficult due to biopsies 
feasibility; for this reason, the most easy-to-reach 
peripheral blood mononuclear cells (PBMCs) 
could be a valid “surrogate” to investigate 
intracellular drug concentrations (10-13). 
Our group study showed that TLV plasma 
Ctrough levels were influenced by ATP-binding 
cassette (ABC) B1and B11 SNPs, with a potential 
influence on intracellular levels being the 
involvement of P-glycoprotein(14).  
The aims of this retrospective study carried out 
after 1 month exposure to triple therapy of a cohort 
of HCV-1 genotype infected patients were to, first, 
determine TLV in plasma and, for the first time, in 
PBMCs,  and  second,  evaluate the 
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influence of single nucleotide polymorphisms 
(SNPs) in genes involved in RBV (15) and in TLV 
transport, also SNPs of vitamin D pathway, and 
their correlation with intracellular TLV. 
 
METHODS 
 
Characteristics of the study population 
Chronic hepatitis C affected patients treated with 
PEG-IFNα 2a (180mg/week) plus RBV 
(15mg/Kg/day) for 4 weeks followed by TLV 
(1125mg/12h) enrolled at Amedeo di Savoia 
Hospital (Turin, Italy) between 2012 and 2014 
were enrolled. Inclusion criteria were: HCV-1 
genotype patients without major contraindication 
to IFNα, RBV and TLV therapy, 18 years old, no 
co-infection, no concomitant interacting drugs, no 
IFN, RBV and TLV modification up to week 4 of 
triple therapy and no concomitant vitamin D 
administration. Drop-out patients for any reason 
were excluded from this analysis. 
 Study protocol “HCV-GEN” was approved by 
the local Ethics Committee. A written informed 
consent for the study was obtained from each 
enrolled subject. 
 
Pharmacogenetics analyses 
DNA was extracted from blood using the QIAamp 
DNA Mini Kit (Qiagen, Valencia, CA). Allelic 
discrimination analysis was performed using 
TaqMan assays (Applied Biosystems, Foster City, 
CA) through real-time PCR (BIORAD, Milano, 
Italia). 
 
Plasma RBV and TLV concentrations 
measurement 
RBV and TLV isomers plasma levels were 
determined from samples obtained at the end of 
dosing interval (Ctrough, 12 h ± 3 h) at week 4 of 
triple therapy. Patient samples (collected in the 
lithium-heparin tube, 7 mL) were centrifuged at 
1500 rpm for 10 minutes at 4° C within 30 minutes 
from blood sampling and plasma was stored in 
criovials at –20° C before the analysis. RBV 
concentrations were determined using a high 
performance liquid chromatography system 
coupled with an ultraviolet determination (HLPC-
UV), according to a chromatographic method 
previously published and routinely used in our 
laboratory (16). 
TLV isomers concentrations were determined 
using a validated reverse phase ultra performance 
liquid chromatography tandem mass spectrometry 
method (ULPC-MS/MS)(4).  
 
PBMCs TLV concentrations measurement 
Intra-PBMC TLV isomers concentrations were 
measured through an UPLC–MS/MS coupled with 
On-Line Solid Phase Extraction validated 
method(17). Briefly, PBMC samples were isolated 
by density gradient using CPT vacutainers; the 
resulting extracts were centrifuged and 20 µl of 
supernatants were directly injected into the OSM 
platform (Waters, Milford, MA, USA) for the SPE 
protocol. 
The chromatographic separation was obtained 
on a BEH C18 1.7 um 2.1x150 mm column with a 
gradient of 2 mobile phases: A, water + NH4OH 
and B, acetonitrile:methanol 50:50 (v:v). 
 
Statistical analyses 
For descriptive statistics, continuous variables 
were summarized as median (IQR, interquartile 
range, 25th to 75th percentiles), categorical 
variables were described as frequency and 
percentage.  
All of the SNPs were tested for Hardy-
Weinberg equilibrium by the χ2 test, in order to 
determine the observed genotype frequencies. 
Linkage Disequilibrium (LD) was evaluated with 
Haploview 4.2 software (Cambrige, 
Massachusetts, USA). We measured LD between 
two SNPs using the statistic D': |D'| of 1 indicates 
complete LD, 0 corresponds to absence of LD.  
Correlation between continuous variables was 
performed by Pearson test (r coefficient), 
considering the level of statistical significance (p-
value)<0,05. Kruskal-Wallis and Mann-Whitney 
tests have been used to compare plasma 
concentration between different genotypes 
(p<0.05). Any predictive power of considerable 
variables was finally evaluated through univariate 
(p<0.2) and multivariate (p<0.05) linear regression 
analyses (OR, odd ratio; IC: interval of confidence 
at 95%).  
All the statistic tests were performed with IBM 
SPSS Statistics 20.0 per Windows (Chicago, 
Illinois, USA). 
 
RESULTS 
 
Characteristics of patients 
Ten patients were included in this analysis: their 
characteristics were collected in Table 1. 
 
Pharmacogenetics Analyses 
All the studied SNPs were in Hardy-Weinberg 
equilibrium; variant allele frequencies were 
resumed in Table 2.  
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Table 1. Demographic and clinical characteristics of HCV-1 patients 
Number of patients, n 10 
Male, n (%) 9 (90) 
Naive patients, n (%) 1 (10) 
Previous treatment outcome, n (%)   
-null responders 2 (20) 
-partial responders 0 (0) 
-relaspers 7 (70) 
Median age (IQR) 43 (37-55) 
Median BMI, Kg/m2 (IQR) 27.6 (24.89-29.84) 
Caucasians, n (%) 10 (100) 
Median HCV-RNA at baseline, log IU/mL (IQR)  577653.5 (180578-4122331) 
Median ALT at baseline, IU/L (IQR) 79.5 (44-151) 
Metavir score, n (%)   
F0 2 (20) 
F1 3 (30) 
F2 0 (0) 
F3 2 (20) 
F4 3 (30) 
RBV dose, n (%)   
1200 mg/day 2 (20) 
1000 mg/day 5 (509 
800 mg/day 1 (1) 
IQR, interquartile range; BMI, body mass index; ALT,  alanine aminotransferase; Values in brackets 
are range of standard deviation.No differences concerning demographic, racial, physical 
characteristics and biochemical parameters (Table 1) were observed among genetically defined 
groups. 
 
Only IL28B_rs12979860 and rs8099917 SNPs 
resulted in complete LD (D'=1) in our population. 
None  of the analyzed SNPs were statistically 
associated with TLV PBMC exposure. 
 
Ctrough Analyses 
Median TLV plasma Ctrough was 2579 ng/mL (IQR 
1476-2903 ng/mL) of S and 2233 ng/mL (IQR 
1288-2488 ng/mL) of R isomers. Median S/R 
plasma ratio was 1.11 (IQR 1.01-1.27).  
Median value obtained for intra-PBMCS 
levels was 6863 ng/mL (IQR 5383-7908 ng/mL) 
and 1096 ng/mL (IQR 747-1976 ng/mL) for R. 
Median intra-PBMCS/R ratio was 5.73 (IQR 3.68-
8.10), whereas S-TLV in PBMC/plasma ratio was 
2.59 (IQR 2.29-4.30). A significant correlation 
between RBV plasma concentration and plasma S-
TLV (p =0.708; p=0.022), R (p =0.764; p=0.010) 
and S-TLV in PBMC/plasma ratio (p= -0.702; 
p=0.024) was found; plasma R-TLV correlated 
with S-TLV in PBMC/plasma ratio (p = -0.721; 
p=0.019). Plasma S/R was significantly correlated 
with S-TLV in PBMC/plasma ratio (p = -0.759; 
p=0.011).  
In linear regression analysis, only 
CYP24A1_rs2585428 SNP (p=0.003; OR:-2567; 
IC95%:-3933--1202) and body mass index (BMI, 
p=0.038; OR:263; IC95%:19-507) were 
predictable of the intra-PBMC S levels. 
 
DISCUSSION 
 
TLV specifically blocks HCV polyprotein 
processing by covalently and reversibly binding to 
the active–site serine of viral NS3-4A protease 
(18). It is metabolized in the liver through 
hydrolysis, oxidation and reduction reactions by 
CYP3A4. TLV predominant inactive metabolites
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Table 2.Variants allele frequencies in patients described in Table 1. 
SNPs Wild-type allele: % Mutant allele: % 
ABCB1 +3435 C>T 56.85 (C) 43.15 (T) 
ABCB1 +1236 C>T 56.8 (C) 43.2 (T) 
ABCB1 2677 G>T 54.55 (G) 45.45 (T) 
ABCB11 1131 T>C 27.25 (T) 72.75 (C) 
IL28B rs12979860 T>C 54.55 (T) 45.45 (C) 
IL28B rs12980275 G>A 59.1 (G) 40.9 (A) 
IL28B rs8099917 T>G 59.05 (T) 40.95 (G) 
ITPA rs1127354 C<A 84.05 (C) 15.95 (A) 
ITPA rs7072101A>C 88.65 (A) 11.35 (C) 
ITPA rs6051702 A>C 86.35 (A) 13.65 (C) 
NT5C2 rs10883841 T>C 90.9 (T) 9.1 (C) 
HNF4a rs1884613 C>G 81.85 (C) 18.15 (G) 
SLC28A2 -146 A>T 34.05 (A) 56.95 (T) 
SLC28A2 225 A>C 36.35 (A) 63.65 (C) 
SLC28A2 124 C>T 47.7 (C) 52.3 (T) 
SLC28A3 338 T>C 97.75 (T) 2.25 (C) 
SLC29A1 rs747199 C>G 81.85 (C) 18.15 (G) 
SLC29A1 rs760370 A>G 56.8 (A) 43.2 (G) 
CYP27B1 2838 C>T 74.95 (C) 25.05 (T) 
CYP27B1 1260 G>T 25.05 (G) 74.95 (T) 
CYP24A1 rs2248359 T>C 40.85 (T) 59.15 (C) 
CYP24A1 rs2585428 A>G 43.2 (A) 56.8 (G) 
CYP24A1 rs927650 C>T 45.45 (C) 54.55 (T) 
VDR ApaI C>A 70.45 (C) 29.55 (A) 
VDR TaqI T>C 56.85 (T) 43.15 (C) 
VDR BsmI G>A 75 (G) 25 (A) 
VDR FokI T>C 27.3 (T) 72.7 (C) 
VDR Cdx2 A>G 20.4 (A) 79.6 (G) 
ABCB1/11, ATP-binding cassette 1/11; IL28B, interleukin 28B; ITPA, inosine triphosphate 
pyrophosphatase; NT5C2, cytosolic 5′-nucleotidase 2; HNF4α, hepatocyte nuclear factor 4; 
SLC 28A2/3 and 29A1, solute c carrier 28A2/3 and 29A1; CYP 27B1/24A1, cytochrome 
P450 27B1/24A1; VDR, vitamin D receptor. 
 
are R-diastereomer (30-fold less active), 
pyrazinoic acid and a reduced α-ketoamide bond 
one(19).Weiss et al. showed that this drug is a 
moderate inhibitor and substrate of P-glycoprotein 
and an strong inductor of ABCG2 (20). TLV is 
eliminated in faeces (82%), expired air (9%) and 
urine (1%)(19). PEG-IFNα increases TLV steady 
state (22%), Cmax and AUC (30-40%)(21). 
In this paper, we show, for the first time, that 
despite a lack stereoselectivity in plasma, intra-
PBMC levels of S were about 5-fold greater than 
the R enatiomer. Furthermore, we confirmed  the 
observation (22) that RBV plasma levels were 
directly correlated with S-TLV plasma 
concentrations, consequently with S-TLV in 
PBMC/plasma ratio following the administered 
fix-dose regimen. Conversely, we found that RBV 
is also correlated with R-isomer plasma exposure. 
This aspect has not yet been fully clarified, 
although several hypotheses have been formulated 
(6, 23): probably, the glomerular filtration activity 
reduction, due to TLV administration, could lead 
to minor RBV excretion, thus its higher plasma 
concentrations. 
In linear regression analysis, we found that 
BMI and a polymorphism in CYP24A1 gene were 
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able to predict S intracellular levels. Particularly, 
BMI was a positive predictor factor, whereas 
CYP24A1 SNP was a negative one. 
Many immune mechanisms have been 
identified for spontaneous viral clearance and for 
the success of antiviral therapy(24, 25). 
The activated vitamin D is an important 
immunomodulator and most of its biological 
effects are mediated through vitamin D receptor 
(VDR)(26).  
Polymorphisms in genes of enzymes involved 
in vitamin D inactivation are important for prostate 
cancer prognosis(27) and HCV-2/3PEG-
IFNα/RBV treatment outcomes; particularly, 
CYP24A1_rs2585428GG positively predicts 
therapeutic failure and negatively early virological 
response(28). 
Intra-PBMCs pharmacokinetics of TLV 
deserve further investigation to better understand 
the role of intracellular drug concentrations in 
determining treatment efficacy and toxicity.  
TLV therapeutic drug monitoring could be 
useful tool for the management of HCV infected 
patients(29) and the knowledge of intracellular 
penetration mechanism may be the key factor to 
improve treatment outcome. 
Also concerning BOC, a study by our group 
suggested a positive and significant correlation 
between plasma and PBMC levels.  Moreover, we 
revealed that plasma levels of S-BOC active 
isomer and a polymorphism in the vitamin D 
receptor were able to predict S-intracellular 
exposure, whereas SNPs in aldo-keto reductase 1, 
breast cancer resistance protein1and solute carrier 
family 28genes predicted S-TLV in PBMC/plasma 
ratio(30). 
Our preliminary data could increase the 
understanding of mechanisms underlying TLV 
intracellular and plasma exposure, suggesting the 
implementation of pharmacogenetics in these drug 
kinetic studies. 
Sample size is the main limitation of this study, 
thus these tests have to be confirmed in a wider 
cohort of patients. It could be useful to evaluate 
intracellular RBV concentration data to better 
understand the mechanisms underlying its 
interaction with TLV.  
To date, in several countries, new Direct-
acting antivirals have been approved, opening the 
new era of IFN-free, reducing duration and 
increasing success rate therapy. 
A similar approach should be useful for the 
study of these new drugs, to promptly understand 
pharmacogenetic factors involved in the regulation 
of their plasma and intracellular pharmacokinetics. 
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